Edmonton and Toronto, August 12, 2015 – SinoVeda Canada Inc. and Exzell Pharma Inc. today announced the signing of an exclusive license agreement to commercialize Effecti-Cal® in Canada, the U.S., Australia and New Zealand. The agreement includes upfront and milestone payments, as well as royalties on sales. The specific terms of the transaction were not disclosed.

Effecti-Cal® is approved by Health Canada as a Natural Health Product to support the development and maintenance of healthy bones and teeth. Effecti-Cal® is a source of highly soluble and absorbable calcium, magnesium, and zinc that can be taken with or without food. Effecti-Cal® is well tolerated and has fewer side effects. Gastrointestinal side effects such as constipation, gas, bloating, and abdominal pain are commonly caused by other calcium supplements, but not with Effecti-Cal®.

Dr. Yun Tam, President, Chief Scientific Officer, and Co-founder of SinoVeda Canada Inc. stated, “We are extremely pleased with this first commercial deal for Effecti-Cal®. The bone health marketplace is sorely lacking in products that have meaningful scientifically validated benefits, and we are pleased to be working with Exzell Pharma to make Effecti-Cal® available to consumers in these first markets.”